VuuAI and Amiculum partner to transform content engagement in pharma
December 2, 2025 | artificial intelligence, healthcare communications
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of VuuAI’s novel technology, which is positioned to transform the pharma commercialization model.
VuuAI brings a novel GenAI platform that allows the rapid validation of compliance and pharma brand integrity, plus optimization, transformation and creation of brand and disease area content. The platform is backed by an industry team with significant experience spanning content, technology, medical and commercial operations, and enterprise-level workflow transformation. In the future, users of VuuAI are expected to be able to generate dynamic, personalized and approved marketing and medical content instantaneously, in any format, for delivery via any channel.
The companies will collaborate to partner with pharma and medtech clients in deploying and scaling the platform, aligning VuuAI’s platform with Amiculum’s broader commercial, medical, data security, project and change management capabilities, to ensure optimal results with maximum efficiency for clients.
Amiculum has made a strategic financial investment in VuuAI, as part of an open seed funding round, and will also be contributing pharmaceutical marketing and medical communications expertise as the product is further developed.
Launch of the first product is expected in early 2026, with engagement already underway with several customers under terms that enable early access, input into features and significant licensing incentives. Companies using VuuAI will benefit from massive efficiencies in production while also enabling more effective, personalized and relevant content, driving better results for brands, HCPs and patients.
Commenting on the agreement, Dr Jenny Putin, Amiculum Co-founder said:
‘This is a very exciting development for Amiculum and supports our ambition to be a leading technology-enabled independent global healthcare communications agency within the pharmaceutical industry.’
Dr Paul Tunnah, VuuAI CEO and Co-founder stated:
‘ VuuAI has the potential to completely reimagine the future engagement model of pharmaceutical companies and their agencies. We are delighted to be partnering with Amiculum. Our collaboration will help our clients to see immediate benefit from the technology, while also supporting further development.’
More about Amiculum
Amiculum is a leading, independent global healthcare consulting and communications agency. Headquartered in the UK, the company has a team of over 300 people worldwide, with backgrounds in biomedical science, brand communications, patient advocacy, digital strategy, design and more.
For over two decades, Amiculum has been partnering with visionary pharmaceutical and biotechnology companies in collaboration with medical experts and patients to amplify groundbreaking science and engage audiences and enable transformation of health.
For more information about Amiculum’s team and services, visit the website (https://amiculum.biz) or email: contact@amiculum.biz
Amiculum: Defined by intelligence. Driven by curiosity. Enabled by technology.
More about VuuAI
VuuAI transforms commercial and medical engagement using AI-powered automation to empower pharma and medtech teams to efficiently produce compliant, on-brand, and effective content, thereby accelerating the adoption of medical innovation.
The VuuAI team has unparalleled life sciences experience spanning content, technology, workflow optimization and enterprise-level transformation.
Investors and pharma / medtech customers can find out more information on VuuAI at the website: https://www.vuu.ai/ or by emailing hello@vuu.ai.
This content was provided by Amiculum
Company Details
Latest Content from Amiculum
Winning in Pharma: the power of early strategic planning with patients
By Zoë van Helmond
Turn payer insights into impact with omnichannel engagement in market access
By Betty Charleshouse
How can pharma build genuine partnerships with patient communities?
Patient engagement is not optional in pharma – it’s integral. Meaningful partnerships with patients, caregivers and advocates must shape every stage of healthcare and medicines development, driving better outcomes, equity...
Amiculum earns EcoVadis silver medal for the 3rd year running
We’re proud to announce that we have once again strengthened our commitment to sustainability! Our 2025 EcoVadis reassessment has resulted in a score of 75/100, allowing us to maintain our...
AI persona generation for healthcare: quick wins & real-world impact
By Aaron Fletcher
VuuAI and Amiculum partner to transform content engagement in pharma
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of...
Does real-world use of AI in systematic literature reviews result in time and cost savings?
By Manca Povsic and Emma Griffiths